Details for Patent: 9,139,536
✉ Email this page to a colleague
Which drugs does patent 9,139,536 protect, and when does it expire?
Patent 9,139,536 protects VIEKIRA XR and VIEKIRA PAK (COPACKAGED) and is included in two NDAs.
This patent has forty-five patent family members in twenty-one countries.
Summary for Patent: 9,139,536
Title: | Anti-infective agents and uses thereof |
Abstract: | This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. |
Inventor(s): | Flentge; Charles A. (Salem, WI), Hutchinson; Douglas K. (Antioch, IL), Betebenner; David A. (Libertyville, IL), DeGoey; David A. (Salem, WI), Donner; Pamela L. (Mundelein, IL), Kati; Warren M. (Gurnee, IL), Krueger; Allan C. (Gurnee, IL), Liu; Dachun (Waukegan, IL), Liu; Yaya (Buffalo Grove, IL), Longenecker; Kenton L. (Grayslake, IL), Maring; Clarence J. (Palatine, IL), Motter; Christopher E. (Oak Creek, WI), Pratt; John K. (Kenosha, WI), Randolph; John T. (Libertyville, IL), Rockway; Todd W. (Grayslake, IL), Stewart; Kent D. (Gurnee, IL), Wagner; Rolf (Antioch, IL), Chen; Shuang (Gurnee, IL), Gao; Yi (Vernon Hills, IL), Lou; Xiaochun (Long Grove, IL), Zhang; Geoff G. Z. (Libertyville, IL) |
Assignee: | AbbVie Inc. (North Chicago, IL) |
Application Number: | 13/838,223 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,139,536
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF HCV INFECTION USING DASABUVIR | ⤷ Try a Trial | ||||
Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF HCV INFECTION USING DASABUVIR | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,139,536
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | E519746 | ⤷ Try a Trial | |||
Canada | 2699986 | ⤷ Try a Trial | |||
Canada | 2849420 | ⤷ Try a Trial | |||
China | 101842360 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |